Oncology Central

Evaluation of contemporary platinum-doublet chemotherapy-modified dose and schedules


Often in clinical practice, dose modifications in the form of dose reductions or delays are warranted in response to treatment-related toxicity with systemic therapy administration [1,2]. However, this practice may raise concern about its impact on therapeutic benefit. Current guidelines from the National Comprehensive Cancer Network favor administration of systemic therapy (depending on the line) for patients with advanced-stage non-small-cell lung cancer (NSCLC) in good performance status, independent of their age.

Restricted Content / Members Only

You cannot view this content because It is available to members only. Please or Register to view this area.




News Headlines

Leave A Comment

Please wait...

Would you like access to more immuno-oncology content?

Register with Oncology Central to find out the latest news, opinions and journal articles published in the oncology field by leading experts.